sls009
Generic: tambiciclib·Code: SLS009
sls009: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML
Frequently asked questions
Who is developing sls009?
sls009 is being developed by SELLAS Life Sciences Group, Inc..
How many clinical trials involve sls009?
BioSniper tracks 1 clinical trial involving sls009.
Get deeper analysis on sls009
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis